Companies › Pharvaris Netherlands
1 active drug program in 2 registered trials: 2 Phase 3; Immunology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Deucrictibant Plasma kallikrein inhibitor | KLKB1 | Phase 3 | Hereditary Angioedema (HAE); Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06669754 | Deucrictibant | Phase 3 | Hereditary Angioedema (HAE) | Immunology | Jul 2026 |
| NCT07266805 | Deucrictibant | Phase 3 | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Immunology | Jun 2027 |
Kyowa Kirin KalVista Pharmaceuticals BioCryst Pharmaceuticals ADARx Pharmaceuticals DiaMedica Therapeutics
KalVista Pharmaceuticals BioCryst Pharmaceuticals AUG Therapeutics Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.